Tegoprazan CAS 942195-55-3 Purity ≥99.0% (HPLC)
Ruifu Chemical is the leading manufacturer and supplier of Tegoprazan (CAS: 942195-55-3) with high quality, Please contact:alvin@ruifuchem.com
Intermediates of Tegoprazan
Tegoprazan CAS: 942195-55-3
(R)-5,7-Difluorochroman-4-ol CAS: 1270294-05-7
4-Hydroxy-N,N,2-trimethyl-1-tosyl-1H-benzo[d]imidazole-6-carboxamide CAS: 942195-86-0
1-Benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid CAS: 1640981-19-6
| Chemical Name | Tegoprazan |
| Synonyms | 7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide; CJ-12420; RQ-00000004 |
| CAS Number | 942195-55-3 |
| Stock Status | In Stock, Commercial Production |
| Molecular Formula | C20H19F2N3O3 |
| Molecular Weight | 387.38 |
| Boiling Point | 596.5±50.0℃ (Predicted) |
| Density | 1.371±0.06 g/cm3 |
| Storage Condition | Store at 2-8℃, away from light, inert gas |
| COA & MSDS & MOA | Available |
| Shipping Temperature | Normal |
| Origin of Product | Shanghai, China |
| Product Categories | Tegoprazan; API |
| Brand | Ruifu Chemical |
| Item | Specifications | Results |
| Appearance | Off-white to Light Yellow Powder | Conforms |
| 1 H NMR Spectrum | Consistent with structure | Conforms |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.9% |
| Total Impurities | ≤1.0% (HPLC) | 0.1% |
| Loss on Drying | ≤0.50% | 0.18% |
| Residue on Ignition | ≤0.20% | 0.05% |
| Test Standard | Enterprise Standard | Conforms |
Package:Bottle, 100g/500g/bag, 1kg/bag, 25kg/drum, or according to customer's requirement
Storage Condition:Store in sealed containers at cool and dry place (2-8℃); Protect from light and moisture.
Shipping: Deliver to worldwide by air, by sea, by FedEx / DHL Express. Provide fast and reliable delivery.
Tegoprazan (CAS: 942195-55-3) was approved by the Ministry of Food and Drug Safety (MFDS) for marketing in July 2018 for the treatment of gastroesophageal reflux disease and erosive esophagitis. Tegoprazan was originally developed by Pfizer. In 2008, it was licensed to RaQualiaPharma (separated from Pfizer) for joint development. In 2014, Tegoprazan was licensed to CJHealthCare by RaQualiaPharma. Finally, CJHealthCare was successfully developed and marketed in Korea. The drug was first marketed in South Korea.
Tegoprazan is used for remedying and treating nocturnal acid breakthrough symptoms, such as GERD, ulcer, Barrett''s esophagus, and heartburn.
Intermediates of Tegoprazan:
Tegoprazan CAS: 942195-55-3
(R)-5,7-Difluorochroman-4-ol CAS: 1270294-05-7
4-Hydroxy-N,N,2-trimethyl-1-tosyl-1H-benzo[d]imidazole-6-carboxamide CAS: 942195-86-0
1-Benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid CAS: 1640981-19-6
